Merck & Co., Inc. (MRK) Reports Promising Skin Cancer Trial Results for Keytruda and Personalized mRNA Vaccine

What happened: Baillie Gifford's Q3 2026 investor letter for its International Concentrated Growth Strategy highlighted Merck & Co., Inc. Why it matters: The letter said the trial provided significant new evidence that the personalized mRNA vaccine used alongside Keytruda significantly improved survival rates. The strategy said company-specific developments in biotechnology helped offset weakness in parts of the semiconductor supply chain and luxury-goods holdings. Market: +2.4% today ($150.84), +42.7% YTD, 0.3x vol — as of 15:47 UTC

Baillie Gifford's Q3 2026 investor letter for its International Concentrated Growth Strategy highlighted Merck & Co., Inc.

The letter said the trial provided significant new evidence that the personalized mRNA vaccine used alongside Keytruda significantly improved survival rates. The strategy said company-specific developments in biotechnology helped offset weakness in parts of the semiconductor supply chain and luxury-goods holdings. Market: +2.4% today ($150.84), +42.7% YTD, 0.3x vol — as of 15:47 UTC